Literature DB >> 23273194

Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.

Y T Ong1, K A Kirby, A Hachiya, L A Chiang, B Marchand, K Yoshimura, T Murakami, K Singh, S Matsushita, S G Sarafianos.   

Abstract

KD-247 is a humanized monoclonal antibody that targets the third hypervariable (V3) loop of gp120. It can efficiently neutralize a broad panel of clade B, but not non-clade B, HIV-1 isolates. To overcome this limitation, we are seeking to prepare genetically-engineered single-chain variable fragments (scFvs) of KD-247 that will have broader neutralizing activity against both clade B and non-clade B HIV-1 isolates. Initial attempts of optimizing the expression of KD-247 scFv have resulted in the formation of insoluble protein. Therefore, we have established purification protocols to recover, purify, and refold the KD-247 scFv from inclusion bodies. The protocol involved step-wise refolding of denatured scFv by dilution, dialysis, and on-column nickel-affinity purification. Monomeric scFv was further purified by size-exclusion chromatography. Using far UV circular dichroism (CD) spectroscopy we confirmed the expected beta-sheet profile of the refolded KD-247 scFv. Importantly, the refolded KD-247 scFv showed neutralizing activity against replication-competent HIV-1 BaL and JR-FL Env pseudotyped HIV-1, at potency comparable to that of the native full-size KD-247 antibody. Ongoing studies focus on the application of this system in generating KD-247 scFv variants with the ability to neutralize clade B and non-clade B HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273194      PMCID: PMC3612353     

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  40 in total

1.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

Authors:  C Rizzuto; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

Review 2.  Antibody engineering.

Authors:  J Maynard; G Georgiou
Journal:  Annu Rev Biomed Eng       Date:  2000       Impact factor: 9.590

3.  Chemokine receptors and HIV entry.

Authors:  R W Doms
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

Review 4.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

5.  Rapid refolding and polishing of single-chain antibodies from Escherichia coli inclusion bodies.

Authors:  Jessica R Sinacola; Anne S Robinson
Journal:  Protein Expr Purif       Date:  2002-11       Impact factor: 1.650

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Authors:  Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Edwin DeJesus; Roberto C Arduino; Joel E Gallant; Paul Volberding; Robert L Murphy; Fred Valentine; Emily L Nelson; Prakash R Sista; Alex Dusek; J Michael Kilby
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

8.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  3 in total

1.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

2.  Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing.

Authors:  Caitlin A Kowalsky; Matthew S Faber; Aritro Nath; Hailey E Dann; Vince W Kelly; Li Liu; Purva Shanker; Ellen K Wagner; Jennifer A Maynard; Christina Chan; Timothy A Whitehead
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

3.  A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.

Authors:  Linlin Gu; Valentina Krendelchtchikova; Alexandre Krendelchtchikov; Robert A Oster; Kohtaro Fujihashi; Qiana L Matthews
Journal:  Virol J       Date:  2014-06-16       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.